Combination treatment overcomes PARPi resistance in ovarian cancer by enhancing DNA damage and immune response through cGAS-STING activation, increasing CD8+ T cell infiltration, and improving tumor suppression. Shows promise for broader therapeutic impact. This evidence concerns the gene STING1 and neoplasm.